Press Room 2021

Wednesday, 24 November 2021 05:22

MesenCure treatment resulted in a survival rate of 94% of the severe patients treated and reduced their hospitalization period by about half

Analysis of results obtained from a phase II, multi-center clinical trial in severe Covid-19 patients treated with Bonus BioGroup's drug product MesenCure, showed that; MesenCure treatment resulted in a survival rate of 94% of the severe patients treated and reduced their hospitalization period by about half Bonus BioGroup (TASE: BONS)…

Sunday, 17 October 2021 05:21

A patent approval secures Bonus BioGroup protection for the exclusivity of use and commercialization in Europe, in addition to the US, of Engineered Nanoparticle Technology, which may enable the development of a variety of therapies for the accelerat

A patent approval secures Bonus BioGroup protection for the exclusivity of use and commercialization in Europe, in addition to the US, of Engineered Nanoparticle Technology, which may enable the development of a variety of therapies for the acceleration of the repair of injured tissue or tissue loss Bonus BioGroup (TASE:…

Sunday, 03 October 2021 05:21

Moshe Bar Siman Tov, former CEO of the Israeli Ministry of Health, joins the Business Advisory Board of Bonus BioGroup

Moshe Bar Siman Tov,former CEO of the Israeli Ministry of Health, joins the Business Advisory Board of Bonus BioGroup Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and cell therapy products. Bonus BioGroup is pleased to announce the addition of…

Monday, 29 August 2022 05:20

Bonus BioGroup is preparing to adjust its manufacturing capacity for an increase in severe Covid-19 patients - leased a building at Matam Park, Haifa

Following the approval by the Israeli Ministry of Health for additional medical centers to join in phase II clinical trial for the treatment of severe Covid-19 with Bonus BioGroup's drug product MesenCureBonus BioGroup is preparing to adjust its manufacturing capacity for an increase in severe Covid-19 patients - leased a…

Wednesday, 11 August 2021 05:19

The Israeli Ministry of Health approved the joining of additional medical centers to the Phase II clinical trial for severe Covid-19 evaluating Bonus BioGroup's product MesenCure

As Covid-19 infections are rising and in light of significant improvements in the health and recovery of severe Covid-19 patients treated with MesenCure;The Israeli Ministry of Health approved the joining of additional medical centers to the Phase II clinical trial for severe Covid-19 evaluating Bonus BioGroup's product MesenCure Bonus BioGroup…

Wednesday, 07 July 2021 05:19

Bonus BioGroup demonstrated significant improvement in parameters indicating reduced tissue damage, including muscle tissue, in addition to alleviating pneumonia in severe Covid-19 patients treated with the advanced cell therapy product MesenCure

In view of the spread of new variants of coronavirus, reduced vaccine effectiveness, and the imminent rise in Covid-19 incidence;Bonus BioGroup demonstrated significant improvement in parameters indicating reduced tissue damage, including muscle tissue, in addition to alleviating pneumonia in severe Covid-19 patients treated with the advanced cell therapy product MesenCure…

Thursday, 27 May 2021 05:18

Bonus BioGroup presented complete success in treating COVID-19 patients with MesenCure, which significantly improved the patients’ health

At the International Society for Cell & Gene Therapy (ISCT) 2021 annual meeting in New Orleans,Bonus BioGroup presented complete success in treating COVID-19 patients with MesenCure, which significantly improved the patients’ healthThe Israel Ministry of Health approved the phase II clinical trial for the treatment of life-threatening respiratory distress with…

Wednesday, 17 March 2021 04:59

Bonus BioGroup developed a network of artificial blood vessels, intended to enable better integration of transplanted lab-grown organs

Bonus BioGroup developed a network of artificial blood vessels, intended to enable better integration of transplanted lab-grown organsA US granted patent provides Bonus BioGroup with exclusive rights for the development and marketing of its network of artificial blood vessels, which may become an essential component in tissue engineering Bonus BioGroup…

Tuesday, 19 January 2021 04:59

Bonus BioGroup received all the necessary approvals to conduct a clinical trial to evaluate MesenCure for the treatment of Covid-19

Following safety and efficacy preclinical results of the unique drug product MesenCure, a therapy specifically developed by Bonus BioGroup for the life-threatening acute respiratory distress in coronavirus (Covid-19) patients and pneumonia; Bonus BioGroup (TASE: BONS) is a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue-engineered and…

Press Room

Press Releases 2021